Abstract 62P
Background
Insulin-like growth factor (IGF) and insulin-like growth factor binding protein (IGFBP) are the major components in the IGF axis that play an important role in the development and progression of cancer. However, little is known about the circulatory levels of these proteins with recurrence and metastasis in breast carcinoma (BC).
Methods
One hundred and twenty-eight (128) breast cancer patients who underwent mastectomy were purposively taken from a prospective study. Clinicopathological information was collected from patients’ medical records. Anthropometric and biochemical parameters were measured by standard methods. Growth and metabolic factors were estimated by enzyme-linked immunosorbent assay (ELISA), and compared for patients’ recurrence and metastasis.
Results
The mean age at diagnosis was 44 years. Most of the tumors (94%) were ductal cell carcinoma. Two thirds were moderately differentiated tumor grade and lymph node positive [70% and 67% respectively]. Circulatory levels of IGFBP1 were significantly higher (p<0.05) in patients who received adjuvant chemotherapy; and patients with recurrence and metastasis while IGF1 was found to be significantly increased in only metastatic breast cancer (p<0.05). IGFBP-1 levels were correlated with SGPT, ALP, hemoglobin, WBC, ESR, CA15.3 and contraceptive use, whereas, IGF-1 was associated with insulin, HOMA %B and ESR.
Conclusions
High serum levels of IGFBP-1 and IGF-1 may be associated with breast cancer recurrence and metastasis. These results need to be confirmed in larger breast cancer survivor cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
TWAS, Ministry of Education (MoE) Bangladesh.
Funding
The World Academy of Sciences (TWAS), Trieste, Italy. Bangladesh Bureau of Educational Information & Statistics (BANBEIS), Ministry of Education (MoE), Dhaka, Bangladesh.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session